Jeryl L Hilleman - Net Worth and Insider Trading

Jeryl L Hilleman Net Worth

The estimated net worth of Jeryl L Hilleman is at least $1 Million dollars as of 2023-09-25. Jeryl L Hilleman is the CFO of Intersect ENT Inc and owns about 31,884 shares of Intersect ENT Inc (XENT) stock worth over $900,404. Jeryl L Hilleman is the Director of SI-BONE Inc and owns about 15,349 shares of SI-BONE Inc (SIBN) stock worth over $324,631. Jeryl L Hilleman is also the Director of NovoCure Ltd and owns about 2,537 shares of NovoCure Ltd (NVCR) stock worth over $44,017. Besides these, Jeryl L Hilleman also holds Minerva Neurosciences Inc (NERV) , Amyris Inc (AMRSQ) . Details can be seen in Jeryl L Hilleman's Latest Holdings Summary section.

Transaction Summary of Jeryl L Hilleman

Jeryl L Hilleman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jeryl L Hilleman owns 9 companies in total, including SI-BONE Inc (SIBN) , Minerva Neurosciences Inc (NERV) , and NovoCure Ltd (NVCR) among others .

Click here to see the complete history of Jeryl L Hilleman’s form 4 insider trades.

Insider Ownership Summary of Jeryl L Hilleman

Ticker	Comapny	Transaction Date	Type of Owner
SIBN	SI-BONE Inc	2019-12-03	director
NERV	Minerva Neurosciences Inc	2018-07-16	director
NVCR	NovoCure Ltd	2018-07-31	director
XENT	Intersect ENT Inc	2014-07-23	Chief Financial Officer
XNPT	XenoPort Inc	2016-07-05	director
OCRX	Ocera Therapeutics Inc	2013-12-19	CFO and Secretary
AMRSQ	Amyris Inc	2011-04-15	Chief Financial Officer
TLIS	Talis Biomedical Corp	2021-03-16	director
HLVX	HilleVax Inc	2022-04-28	director

Jeryl L Hilleman Latest Holdings Summary

Jeryl L Hilleman currently owns a total of 5 stocks. Among these stocks, Jeryl L Hilleman owns 31,884 shares of Intersect ENT Inc (XENT) as of April 2, 2019, with a value of $900,404 and a weighting of 70.90000000000001%. Jeryl L Hilleman owns 15,349 shares of SI-BONE Inc (SIBN) as of June 20, 2023, with a value of $324,631 and a weighting of 25.56%. Jeryl L Hilleman also owns 2,537 shares of NovoCure Ltd (NVCR) as of June 10, 2022, with a value of $44,017 and a weighting of 3.47%. The other 2 stocks Minerva Neurosciences Inc (NERV) , Amyris Inc (AMRSQ) have a combined weighting of 0.08% among all his current holdings.

Latest Holdings of Jeryl L Hilleman

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XENT	Intersect ENT Inc	2019-04-02	31,884	28.24	900,404
SIBN	SI-BONE Inc	2023-06-20	15,349	21.15	324,631
NVCR	NovoCure Ltd	2022-06-10	2,537	17.35	44,017
NERV	Minerva Neurosciences Inc	2019-06-26	125	7.70	963
AMRSQ	Amyris Inc	2011-05-20	594	0.05	27

Holding Weightings of Jeryl L Hilleman

Jeryl L Hilleman Form 4 Trading Tracker

According to the SEC Form 4 filings, Jeryl L Hilleman has made a total of 2 transactions in Intersect ENT Inc (XENT) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Intersect ENT Inc is the sale of 51,200 shares on April 2, 2019, which brought Jeryl L Hilleman around $2 Million.

According to the SEC Form 4 filings, Jeryl L Hilleman has made a total of 3 transactions in SI-BONE Inc (SIBN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in SI-BONE Inc is the sale of 4,162 shares on June 20, 2023, which brought Jeryl L Hilleman around $118,076.

According to the SEC Form 4 filings, Jeryl L Hilleman has made a total of 2 transactions in NovoCure Ltd (NVCR) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in NovoCure Ltd is the sale of 407 shares on June 10, 2022, which brought Jeryl L Hilleman around $28,331.

More details on Jeryl L Hilleman's insider transactions can be found in the Insider Trading History of Jeryl L Hilleman table.

Insider Trading History of Jeryl L Hilleman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jeryl L Hilleman Trading Performance

GuruFocus tracks the stock performance after each of Jeryl L Hilleman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jeryl L Hilleman is 52.6%. GuruFocus also compares Jeryl L Hilleman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jeryl L Hilleman within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jeryl L Hilleman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jeryl L Hilleman

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Relative Return(%)	20.22	52.6	27.83	-34.99	-32.31	-58.14
Relative Return to S&P 500(%)	16.37	50.41	16.64	-38.25	-53.52	-68.47

Jeryl L Hilleman Ownership Network

Ownership Network List of Jeryl L Hilleman

No Data

Ownership Network Relation of Jeryl L Hilleman

Jeryl L Hilleman Owned Company Details

What does SI-BONE Inc do?

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Who are the key executives at SI-BONE Inc?

Jeryl L Hilleman is the director of SI-BONE Inc. Other key executives at SI-BONE Inc include Chief Financial Officer Anshul Maheshwari , 10 percent owner Yasunori Kaneko , and director & 10 percent owner John Gordon Freund .

SI-BONE Inc (SIBN) Insider Trades Summary

Over the past 18 months, Jeryl L Hilleman made 2 insider transaction in SI-BONE Inc (SIBN) with a net sale of 6,086. Other recent insider transactions involving SI-BONE Inc (SIBN) include a net sale of 358,372 shares made by Jeffrey W Dunn , a net sale of 43,684 shares made by Anthony J Recupero , and a net sale of 18,908 shares made by Anshul Maheshwari .

In summary, during the past 3 months, insiders sold 100,553 shares of SI-BONE Inc (SIBN) in total and bought 0 shares, with a net sale of 100,553 shares. During the past 18 months, 532,000 shares of SI-BONE Inc (SIBN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 532,000 shares.

SI-BONE Inc (SIBN)'s detailed insider trading history can be found in Insider Trading Tracker table.

SI-BONE Inc Insider Transactions

No Available Data

What does Minerva Neurosciences Inc do?

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Who are the key executives at Minerva Neurosciences Inc?

Jeryl L Hilleman is the director of Minerva Neurosciences Inc. Other key executives at Minerva Neurosciences Inc include 10 percent owner Ag Boehringer , 10 percent owner Boehringer Ingelheim International Gmbh , and 10 percent owner Plc Barclays .

Minerva Neurosciences Inc (NERV) Insider Trades Summary

Over the past 18 months, Jeryl L Hilleman made no insider transaction in Minerva Neurosciences Inc (NERV). Other recent insider transactions involving Minerva Neurosciences Inc (NERV) include a net sale of 27,394 shares made by Remy Luthringer , a net sale of 22,082 shares made by Geoff Race , and a net sale of 3,580 shares made by Frederick W Ahlholm .

In summary, during the past 3 months, insiders sold 0 shares of Minerva Neurosciences Inc (NERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 53,056 shares of Minerva Neurosciences Inc (NERV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 53,056 shares.

Minerva Neurosciences Inc (NERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Minerva Neurosciences Inc Insider Transactions

No Available Data

What does NovoCure Ltd do?

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

Who are the key executives at NovoCure Ltd?

Jeryl L Hilleman is the director of NovoCure Ltd. Other key executives at NovoCure Ltd include General Counsel Arye Barak Ben , Chief Innovation Officer Uri Weinberg , and Chief Human Resources Officer William Patrick Burke .

NovoCure Ltd (NVCR) Insider Trades Summary

Over the past 18 months, Jeryl L Hilleman made 1 insider transaction in NovoCure Ltd (NVCR) with a net sale of 407. Other recent insider transactions involving NovoCure Ltd (NVCR) include a net sale of 122,201 shares made by Frank X Leonard , a net sale of 25,210 shares made by Pritesh Shah , and a net sale of 11,670 shares made by Ashley Cordova .

In summary, during the past 3 months, insiders sold 2,594 shares of NovoCure Ltd (NVCR) in total and bought 0 shares, with a net sale of 2,594 shares. During the past 18 months, 420,599 shares of NovoCure Ltd (NVCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 420,599 shares.

NovoCure Ltd (NVCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

NovoCure Ltd Insider Transactions

No Available Data

What does Intersect ENT Inc do?

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Who are the key executives at Intersect ENT Inc?

Jeryl L Hilleman is the Chief Financial Officer of Intersect ENT Inc. Other key executives at Intersect ENT Inc include Chief Human Resource Officer Reyna M Fernandez , EVP & GC & Corporate Secretary Patrick A Broderick , and EVP & Chief Financial Officer Richard A Meier .

Intersect ENT Inc (XENT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intersect ENT Inc (XENT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intersect ENT Inc (XENT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intersect ENT Inc (XENT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intersect ENT Inc Insider Transactions

No Available Data

What does XenoPort Inc do?

XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.

Who are the key executives at XenoPort Inc?

Jeryl L Hilleman is the director of XenoPort Inc. Other key executives at XenoPort Inc include See Remarks William G Harris , 10 percent owner & other: Possible Member of 10% Group Deerfield Management Company, L.p. (series C) , and 10 percent owner & other: Possible Member of 10% Group Deerfield Mgmt L.p. .

XenoPort Inc (XNPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XenoPort Inc (XNPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XenoPort Inc (XNPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XenoPort Inc (XNPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

XenoPort Inc Insider Transactions

No Available Data

What does Ocera Therapeutics Inc do?

Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.

Who are the key executives at Ocera Therapeutics Inc?

Jeryl L Hilleman is the CFO and Secretary of Ocera Therapeutics Inc. Other key executives at Ocera Therapeutics Inc include 10 percent owner Brian H Dovey , 10 percent owner Domain Partners Viii, L.p. , and 10 percent owner Dp Viii Associates, L.p. .

Ocera Therapeutics Inc (OCRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ocera Therapeutics Inc (OCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ocera Therapeutics Inc (OCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ocera Therapeutics Inc (OCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocera Therapeutics Inc Insider Transactions

No Available Data

What does Amyris Inc do?

Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.

Who are the key executives at Amyris Inc?

Jeryl L Hilleman is the Chief Financial Officer of Amyris Inc. Other key executives at Amyris Inc include Chief Restructuring Officer Philip J. Gund , CHIEF ACCOUNTING OFFICER Elizabeth E. Dreyer , and director & President and CEO John Melo .

Amyris Inc (AMRSQ) Insider Trades Summary

Over the past 18 months, Jeryl L Hilleman made no insider transaction in Amyris Inc (AMRSQ). Other recent insider transactions involving Amyris Inc (AMRSQ) include a net sale of 4,498,776 shares made by Frank Kung , a net sale of 107,458 shares made by Nicole Kelsey , and a net sale of 81,792 shares made by Hermanus Kieftenbeld .

In summary, during the past 3 months, insiders sold 0 shares of Amyris Inc (AMRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,003,696 shares of Amyris Inc (AMRSQ) were sold and 17,155 shares were bought by its insiders, resulting in a net sale of 4,986,541 shares.

Amyris Inc (AMRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amyris Inc Insider Transactions

No Available Data

What does Talis Biomedical Corp do?

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Who are the key executives at Talis Biomedical Corp?

Jeryl L Hilleman is the director of Talis Biomedical Corp. Other key executives at Talis Biomedical Corp include President & other: Chief Scientific Officer Andrew A Lukowiak , Interim CFO Rebecca Markovich , and director & 10 percent owner Julian Baker .

Talis Biomedical Corp (TLIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Talis Biomedical Corp (TLIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Talis Biomedical Corp (TLIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Talis Biomedical Corp (TLIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talis Biomedical Corp Insider Transactions

No Available Data

What does HilleVax Inc do?

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Who are the key executives at HilleVax Inc?

Jeryl L Hilleman is the director of HilleVax Inc. Other key executives at HilleVax Inc include Chief Financial Officer Shane Maltbie , director & 10 percent owner Patrick J Heron , and 10 percent owner James N Topper .

HilleVax Inc (HLVX) Insider Trades Summary

Over the past 18 months, Jeryl L Hilleman made no insider transaction in HilleVax Inc (HLVX). Other recent insider transactions involving HilleVax Inc (HLVX) include a net purchase of 1,764,706 shares made by Frazier Life Sciences X, L.p. ,

In summary, during the past 3 months, insiders sold 0 shares of HilleVax Inc (HLVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of HilleVax Inc (HLVX) were sold and 1,764,706 shares were bought by its insiders, resulting in a net purchase of 1,764,706 shares.

HilleVax Inc (HLVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

HilleVax Inc Insider Transactions

No Available Data

Jeryl L Hilleman Mailing Address

Above is the net worth, insider trading, and ownership report for Jeryl L Hilleman. You might contact Jeryl L Hilleman via mailing address: C/o Intersect Ent, Inc., 1555 Adams Drive, Menlo Park Ca 94025.

Discussions on Jeryl L Hilleman

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.